#her2
Latest news and interesting information about her2.
Enhertu Gets EU Panel Backing for HER2+ Tumors
Enhertu receives EU panel backing for HER2-positive solid tumors. If approved, it would be the first tumor agnostic HER2 therapy in the EU.
Pfizer SWOT analysis: new drugs
Pfizer SWOT analysis: new drugs Tukysa and anti-obesity strategy to navigate patent cliff.
Relay Therapeutics Launches $175M Stock Offering
Relay Therapeutics launches $175 million stock offering. See details on the offering, zovegalisib progress, and analyst ratings. Bond.az covers the latest.
Relay Therapeutics stock surges 15%
Relay Therapeutics stock surges 15% after positive data from Phase 2 trial for zovegalisib in vascular anomalies.
Genentech to Present Breast Cancer Data at ASCO Meeting
Genentech will present breast cancer data on giredestrant and other drugs at the 2026 ASCO meeting.
...